# Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

> **NCT06159478** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Japan** · enrollment: 32 (estimated)

## Conditions studied

- Low-grade Glioma
- Pancreatic Cancer

## Interventions

- **DRUG:** Binimetinib 15 MG

## Key facts

- **NCT ID:** NCT06159478
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-29
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-09-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159478, "Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06159478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*